Mirum Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 5 Sell calls were actually followed by a +14% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is +19.0% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 10.0% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 80.8% | Better than 91% |
| Operating margin | -4.2% | Better than 17% |
| Net margin | -4.5% | Better than 20% |
| Return on equity | -8.6% | Better than 21% |
| Return on invested capital | -3.8% | Better than 23% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -0.2% | Better than 73% |
| 6-month return | -2.5% | Better than 51% |
| 12-month return (ex latest month) | 17.1% | Better than 55% |
| Distance below 52-week high | 26.1% | Better than 49% |
Financial Health C
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.7x | Better than 69% |
| Debt to assets | 37.9% | Better than 30% |
| Interest coverage | -0.5x | Better than 23% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 65.2% | Better than 74% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 95.51
- Open
- 94.50
- Day range
- 94.10 - 98.39
- Avg price
- 96.96
- Volume
- 1.06M
- Turnover
- 103.00M
- Turnover ratei
- 1.87%
- Volume ratioi
- 2.10
- Amplitudei
- 4.49%
- 52-week rangei
- 63.23 - 130.00
Valuation
- P/Ei
- -204.53
- P/E (TTM)i
- -6.64
- P/Bi
- -115.82
- EPSi
- -0.47
- Book value / shi
- -0.83
- Net profit
- -30.68M
- Net assets
- -54.18M
Share structure
- Market cap
- 6.28B
- Float capi
- 5.45B
- Shares out
- 65.28M
- Float sharesi
- 56.74M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2019-07-18
26.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-10.51M net over the window
Short interest
- Shares short
- 6.52M
- % of floati
- 10.05%
- Days to coveri
- 11.84
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Mirum Pharmaceuticals (MIRM)?
Mirum Pharmaceuticals last traded at 96.13. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Mirum Pharmaceuticals's market cap?
About 6.28B.
What is the P/E ratio of Mirum Pharmaceuticals?
The trailing twelve-month P/E is -6.64. The Valuation tab shows it against the stock's own five-year range.
Does Mirum Pharmaceuticals pay a dividend?
Mirum Pharmaceuticals does not currently pay a regular dividend.
Is Mirum Pharmaceuticals a buy according to analysts?
The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 158.82, which implies 65.2% upside from the current price. This is not investment advice.
What is Mirum Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Mirum Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Mirum Pharmaceuticals discussion 0 comments